Head-to-head · Value Score
bmiMD vs altRX
Two GLP-1 deals, scored on the same six factors. bmiMD lands a Value Score of 89, altRX a 72. Here's who gives you the honest lower price — and where each one bites back.
bmiMD
#11 · Grade A · Great Deal
Est. first month
$99/mo
Save ~93% vs brand-namealtRX
#187 · Grade C · Watch List
Est. first month
From $149/mo (starting dose, compounded)
Save ~89% vs brand-nameThe verdict
bmiMD takes it on Value Score, 89 to 72 — an est. $99/mo first month, with no teaser step-up baked in. altRX isn't out of it: Shoppers who want the only platform offering all four brand-name GLP-1s plus compounded.
Deal-by-deal
The numbers that decide it. Green ✓ marks the stronger side on each line.
| Deal | bmiMD | altRX |
|---|---|---|
| Value Score | 89 (A) | 72 (C) |
| Est. first month | $99/mo | From $149/mo (starting dose, compounded) |
| Save vs brand-name | ~93% | ~89% |
| Semaglutide | $99/mo | From $149/mo (starting dose, compounded) |
| Tirzepatide | $139/mo | From $249/mo (starting dose, compounded) |
| Both molecules | Yes | Yes |
| Pricing | Flat — no step-up | Watch |
| Coverage | All 50 states | Coverage not published |
Factor by factor
The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.
bmiMD
Sub-$100 semaglutide and a low $139 tirzepatide, flat and nationwide — a straight-up low-price play.
Why it's a deal
- $99 flat semaglutide and a low $139 tirzepatide
- Available in all 50 states
- Both molecules priced up front
The fine print
- Not LegitScript-certified — do your own pharmacy diligence
- Thin public track record; no oral or brand-name option
altRX
altRX is a dual-modality telehealth platform offering compounded GLP-1s plus all four brand-name FDA-approved options — Mounjaro, Ozempic, Wegovy, and Zepbound — the most comprehensive brand-name lineup in…
Why it's a deal
- Offers all four brand-name FDA-approved GLP-1s (Mounjaro, Ozempic, Wegovy, Zepbound) — the most comprehensive brand-name access we've reviewed
- LegitScript Certified with a publicly verifiable seal
- Publishes the FDA compounded-medication disclaimer
- Transparent pricing across all six product tiers (compounded plus four brand-name)
- All-inclusive pricing — consult, prescription, and shipping with no hidden fees
The fine print
- States-served list not disclosed
- 503A/503B pharmacy partner not named (only 'multiple USA-certified pharmacies')
- 503A vs 503B designation not specified
- No named medical director
- Corporate physical address not disclosed
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.
Neither one the right fit? Every program that outscores bmiMD is ranked on the bmiMD alternatives board, and the same list for the other side is on alternatives to altRX.
More head-to-heads
Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.